Evaluation of two commercial omalizumab/free IgE immunoassays: Implications of use during therapy

Current Medical Research and Opinion

Volumn 30, Issue 5, 2014, Pages 913-922

  Baker, Dana L ^a   Peng, Kun ^a   Cheu, Melissa ^a   Fischer, Saloumeh Kadkhodayan ^a  

^a GENENTECH INC   (United States)

Author keywords

Dosing table; Enzyme linked immunosorbent assay; IgE; Omalizumab; Pharmacodynamic

Indexed keywords

IMMUNOGLOBULIN E; OMALIZUMAB;

ARTICLE; BIOTEZ ASSAY; BLOOD SAMPLING; COMPARATIVE STUDY; CONTROLLED STUDY; DRUG SCREENING; ENZYME LINKED IMMUNOSORBENT ASSAY; GENENTECH FREE IMMUNOGLOBULIN E ASSAY; HUMAN; IMMUNOASSAY; IMMUNOGLOBULIN BLOOD LEVEL; IN VITRO STUDY; IN VIVO STUDY; VIRACOR IBT FREE IMMUNOGLOBULIN E ASSAY;

ANTI-ASTHMATIC AGENTS; ANTIBODIES, ANTI-IDIOTYPIC; ANTIBODIES, MONOCLONAL, HUMANIZED; ASTHMA; HUMANS; IMMUNOASSAY; IMMUNOGLOBULIN E;

EID: 84899113577     PISSN: 03007995     EISSN: 14734877     Source Type: Journal    
DOI: 10.1185/03007995.2013.877435     Document Type: Article

References (21)

1. Global Initiative for Asthma (GINA). From the global strategy for asthma management and prevention. Available at: Http://www.ginasthma.org [Last accessed 25 November 2013]
2. Burrows B, Martinez FD, Halonen M, et al. Association of asthma with serum IgE levels and skin-test reactivity to allergens. N Engl J Med 1989;320:271-7
3. Holgate S, Casale T, Wenzel S, et al. The anti-inflammatory effects of omalizumab confirm the central role of IgE in allergic inflammation. J Allergy Clin Immunol 2005;115:459-65
4. Ishizaka K, Ishizaka T. Identification of gamma-E-antibodies as a carrier of reaginic activity. J Immunol 1967;99:1187-98
5. Johansson SG, Bennich H. Immunological studies of an atypical (myeloma) immunoglobulin. Immunology 1967;13:381-94
6. Genentech, Novartis US. Xolair FDA Prescribing Information. Available at: Http://www.gene.com/gene/products/information/pdf/xolair-prescribing.pdf [Last accessed 25 November 2013]
7. European Medicines Agency (EMA). Xolair EPAR - product information. Available at: Http://www.ema.europa.eu/docs/en-GB/document-library/EPAR-Product- Information/human/000606/WC500057298.pdf [Last accessed 25 November 2013]
8. Hochhaus G, Brookman L, Fox H, et al. Pharmacodynamics of omalizumab: Implications for optimised dosing strategies and clinical efficacy in the treatment of allergic asthma. Curr Med Res Opin 2003;19:491-8
9. Casale TB, Bernstein IL, Busse WW, et al. Use of an anti-IgE humanized monoclonal antibody in ragweed-induced allergic rhinitis. J Allergy Clin Immunol 1997;100:110-21
10. Hamilton RG, Marcotte GV, Saini SS. Immunological methods for quantifying free and total serum IgE levels in allergy patients receiving omalizumab (Xolair) therapy. J Immunol Methods 2005;303:81-91
11. Fahy JV, Fleming HE, Wong HH, et al. The effect of an anti-IgE monoclonal antibody on the early- And late-phase responses to allergen inhalation in asthmatic subjects. Am J Respir Crit Care Med 1997;155:1828-34
12. Ädelroth E, Rak S, Haahtela T, et al. Recombinant humanized mAb-E25, an anti-IgE mAb, in birch pollen-induced seasonal allergic rhinitis. J Allergy Clin Immunol 2000;106:253-9
13. Strohner P, Staatz A, Sarrach D, et al. The recovery ELISA - A newly developed immunoassay for measurement of therapeutic antibodies and the target antigen during antibody therapy. Clin Chem Lab Med 2012;50:1263-9
14. Lowe PJ, Tannenbaum S, Gautier A, Jimenez P. Relationship between omalizumab pharmacokinetics, IgE pharmacodynamics and symptoms in patients with severe persistent allergic (IgE-mediated) asthma. Br J Clin Pharmacol 2009;68:61-76
15. Hamilton RG. Proficiency survey-based evaluation of clinical total and allergen- specific IgE assay performance. Arch Pathol Lab Med 2010;134:975-82
16. Hamilton RG. Accuracy of Food and Drug Administration-cleared IgE antibody assays in the presence of anti-IgE (omalizumab). J Allergy Clin Immunol 2006;117:759-66
17. Bousquet J, Wenzel S, Holgate S, et al. Predicting response to omalizumab, an anti-IgE antibody, in patients with allergic asthma. Chest 2004;125:1378-86
18. Busse W, Corren J, Lanier BQ, et al. Omalizumab, anti-IgE recombinant humanized monoclonal antibody, for the treatment of severe allergic asthma. J Allergy Clin Immunol 2001;108:184-90
19. Soler M, Matz J, Townley R, et al. The anti-IgE antibody omalizumab reduces exacerbations and steroid requirement in allergic asthmatics. Eur Respir J 2001;18:254-61
20. Bousquet J, Siergiejko Z, Swiebocka E, et al. Persistency of response to omalizumab therapy in severe allergic (IgE-mediated) asthma. Allergy 2011;66:671-8
21. Heaney LG, Robinson DS. Severe asthma treatment: Need for characterising patients. Lancet 2005;365:974-6.